Skip to content
Thursday 13 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,802.53
-0.28%
DAX
26,434.24
+0.39%
CAC 40
8,684.00
+0.10%
STOXX 50
6,561.81
+0.43%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Wednesday 17 March 2021 11:18 am

Which countries in Europe have suspended the Astrazeneca vaccine?

By: Poppy Wood

Add as a preferred source on Google

Fifteen countries across Europe have suspended the rollout of the Astrazeneca vaccine while the EU medicines regulators investigates reports of blood clots among patients.

Sweden yesterday joined a growing list of countries including Italy, Germany, France and Norway to issue a temporary ban on the jab.

State epidemiologist Anders Tegnell said the pause was a “precautionary measure” until the European Medicines Agency (EMA) completes an investigation into reports of several blood clot-related deaths.

No such cases have been reported in Sweden but neighbouring Norway and Denmark have each reported one death.

A further three countries — Austria, Estonia and Lithuania — have suspended vaccinations using certain batches of the Astrazeneca drug.

There were early indications that scepticism regarding the Astrazeneca jab could soon spread to Asia after Thailand also suspended the rollout of the jab earlier this week.

Among 17m people who have received the vaccine in the EU and the UK, 15 cases of deep-vein thrombosis (DVT) and 22 cases of pulmonary embolism have been reported as of 8 March, Astrazeneca said in a statement on Monday.

But the EMA has insisted there is “no indication” that Astrazeneca’s Covid vaccine causes blood clots among patients, noting that the number of thromboembolic was the normal level among the general European population. 

Read more

Sweeping job cuts at GSK to fund £400m Cambridge campus

Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.

Emer Cooke, executive director of the EMA, said the agency remains “firmly convinced” that the benefits of the Astrazeneca vaccine outweigh the risk of side-effects. 

“We know that many thousands of people develop thousands of clots annually for many different reasons”, she added.

The EMA is currently investigating the blood clot reports and will report its findings in a press conference tomorrow, where it is widely expected to reiterate its support for the Astrazeneca jab.

Italy and France this morning vowed to U-turn on their suspension of the Cambridge-based firm’s Covid vaccine if it gets the green light from the EMA tomorrow.

European countries have been accused of playing politics with the jab, after supply shortages slowed down the EU’s vaccine rollout.

Just 8.5 per cent of Europeans have received their first dose of a Covid vaccine, according to the European Centre for Disease Prevention and Control’s Covid-19 Vaccine Tracker. 

That compares to 24.8m people who have received their first injection in the UK — equivalent to around 37 per cent of Britain’s population.

Nicola Magrini, head of Italy’s medicines agency, admitted this morning that the decision to suspend vaccinations was “a political one” that Rome had reached only “because several European countries, including Germany and France, preferred to interrupt”.

Read more

Astrazeneca explores $400bn megadeal with US rival 

AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Politics

Related Topics

  • Coronavirus
  • Re-lockdown
  • Vaccine

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • It’s not just Jason Arday, most of sociology is a scam

  • IT consultant ordered to pay £50,000 after being accused of stealing Soho House members’ personal details

  • Revolut takes flight with launch of new airport lounges

  • As it happened: FTSE 100 falls as Iran and US clash over Strait of Hormuz; Oil stockpiles ‘rapidly depleting’

More from Morning Wire

  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Revolut lands fresh banking licence after wrestling with Europe friction

    Fintech
    Revolut Banque Française ad on a Morris column in Paris, with the July Column and blurred traffic in the background.
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • Alpaca Completes EEA Passporting to 29 Countries, Expanding Access to Regulated Investment Services Across Europe

    Business Wire
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Europe has made a ‘major mistake’ on slow electrification, IEA chief warns 

    Energy
    UK industrial electricity prices are the highest in the G7 and 46 per cent above the average of the International Energy Agency.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook